Abstract
Background A 46-year-old woman presented to a local hospital with acute respiratory failure and a 2-year progressive history of fatigue, personality changes, increased sweating, dysphagia with substantial weight loss, dysarthria, and intermittent ptosis and diplopia. Neurological examination showed facial weakness, lingual atrophy and bulbar palsy, which necessitated the use of a feeding tube and ventilatory support. Mild limb weakness with severe muscle atrophy and diffuse muscle twitches were observed. The patient had also developed visual hallucinations and persecutory delusions. Her personal and family medical histories were unremarkable.
Investigations Sensory and motor nerve conduction studies, repetitive nerve stimulation, electromyogram, blood-cell counts, general chemistry and metabolic function tests, a CT scan, an [18F]fluorodeoxyglucose-PET scan, and tests for serum antibodies to acetylcholine receptors, muscle-specific tyrosine kinase, voltage-gated potassium channels, P/Q-type voltage-gated calcium channels, and paraneoplastic antigens, were carried out.
Diagnosis Myasthenia gravis associated with antibodies to acetylcholine receptor and muscle-specific tyrosine kinase, and Morvan's syndrome associated with antibodies to voltage-gated potassium channels in the absence of thymoma.
Management Combined treatment with prednisone, intravenous immunoglobulin, ciclosporin, and rituximab.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jaretzki A III et al. (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55: 16–23
Evoli A et al. (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126: 2304–2311
Sanders DB et al. (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60: 1978–1980
Illa I et al. (2005) “Seronegative” myasthenia gravis and antiMuSK positive antibodies: description of Spanish series [Spanish]. Med Clin (Barc) 125: 100–102
Vincent A et al. (2004) Seronegative myasthenia gravis. Semin Neurol 24: 125–133
Conti-Fine BM et al. (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116: 2843–2854
Oh SJ et al. (2006) Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis. Muscle Nerve 33: 500–504
Hart IK et al. (2002) Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125: 1887–1895
Buckley C and Vincent A (2005) Autoimmune channelopathies. Nat Clin Pract Neurol 1: 22–33
Saka E et al. (2005) Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 65: 782–783
Lee EK et al. (1998) Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma. J Neurol Neurosurg Psychiatry 65: 857–862
Roohi F et al. (2006) A diagnostic and management dilemma: combined paraneoplastic myasthenia gravis and Lambert-Eaton myasthenic syndrome presenting as acute respiratory failure. Neurologist 12: 322–326
Rudnicki SA and Dalmau J (2005) Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol 18: 598–603
Illa I (2005) IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 252 (Suppl 1): SI14–SI18
Newsom-Davis J (2003) Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol 23: 191–198
Zaja F et al. (2000) Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55: 1062–1063
Hain B et al. (2006) Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 33: 575–580
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Díaz-Manera, J., Rojas-García, R., Gallardo, E. et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat Rev Neurol 3, 405–410 (2007). https://doi.org/10.1038/ncpneuro0526
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0526
This article is cited by
-
AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?
Neurological Sciences (2021)
-
Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis
Journal of Neurology (2019)
-
Current Treatment Options for Peripheral Nerve Hyperexcitability Syndromes
Current Treatment Options in Neurology (2018)
-
A Chinese female Morvan patient with LGI1 and CASPR2 antibodies: a case report
BMC Neurology (2016)
-
Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system
Journal of Neuroinflammation (2016)